Retatrutide
Also known as Reta
A triple-receptor incretin analog studied in metabolic research models.
What it is
Retatrutide (Reta) is an engineered peptide that acts on three incretin pathways at once, GLP-1, GIP, and glucagon receptors. It is a long synthetic sequence that appears in preclinical metabolic research as a triple-agonist reference compound.
How it is studied
Research interest centers on metabolic and glucose-regulation signaling in preclinical models. LNK supplies retatrutide strictly as a research compound. We do not provide dosing, protocols, or any human-use framing.
Purity and COA
Identity testing matters for a long triple-agonist sequence that is easy to get subtly wrong in synthesis. Each batch is confirmed by mass spectrometry for the full sequence and any modification, with HPLC purity documented on the COA you receive.
Further reading
Search the primary literature and registered studies for Retatrutide on independent research databases. LNK is not affiliated with these sources and does not endorse their conclusions.